News Archive

Pembrolizumab

Immunotherapy After Kidney Cancer Surgery Improves Overall Survival

Immunotherapy After Kidney Cancer Surgery Improves Overall Survival

Adjuvant therapy| Cancer patients| Cancer Research| Clear-cell renal-cell carcinoma (ccRCC)| Dr. Toni Choueiri| immunotherapy| KEYNOTE-564| kidney cancer| New England Journal of Medicine| Overall survival| Pembrolizumab| Phase 3 trial

Recently published in the New England Journal of Medicine, findings from the pivotal phase 3 trial, KEYNOTE-564, ...

EMA recommends pembrolizumab for the adjuvant treatment of RCC

EMA recommends pembrolizumab for the adjuvant treatment of RCC

EMA| Pembrolizumab

Urologytimes.com reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

NICE rejects pembro+axitinib therapy for aRCC

NICE rejects pembro+axitinib therapy for aRCC

Axitinib| NICE| Pembrolizumab

Kidney cancer community strongly disagrees with NICE decision not to approve pembrolizumab with axitinib ...

Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced Rcc

Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced Rcc

Axitinib| Pembrolizumab

ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell ...

Europe Adopts Pembrolizumab + Axitinib as 1st-Line Treatment for Advanced RCC

Europe Adopts Pembrolizumab + Axitinib as 1st-Line Treatment for Advanced RCC

Axitinib| Pembrolizumab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), based in ...